Astra Zeneca will need to pay £$30mm (21) for new offices in Sweden to ensure it can still operate in the European Union after Brexit, the company said. CEO Pascal Soriot criticised the lack of clarity over the UK's future relationship with the continent, adding the "wasted money" would be better spent on developing new drugs. He is also concerned that drugs made in the UK will have to be re-tested in Europe if the European Medicines Agency no longer covers Britain after the separation.
Astra Zeneca will need to pay £21m ($30m) for new offices in Sweden to ensure it can still operate in the European Union after Brexit, the company said. CEO Pascal Soriot criticised the lack of clarity over the UK's future relationship with the continent, adding the "wasted money" would be better spent on developing new drugs. He is also concerned that drugs made in the UK will have to be re-tested in Europe if the European Medicines Agency no longer covers Britain after the separation.